Parkinson's Disease Clinical Trial
Official title:
Exercise Targeting Cognitive Impairment in Parkinson's Disease
Verified date | May 2019 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on mild cognitive impairment (MCI) of the executive function (EF) subtype in Parkinson's disease (PD); we hypothesize that skill-based exercise will result in the greatest improvement in EF and lead to modification of underlying neural substrates.
Status | Active, not recruiting |
Enrollment | 25 |
Est. completion date | December 2019 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 85 Years |
Eligibility |
Inclusion Criteria: - willing and able to provide informed consent - confirmed diagnosis of idiopathic PD based on the United Kingdom Brain Bank criteria - Mild cognitive impairment (Level II criteria Movement Disorder Task Force) - medically eligible for MRI imaging - able to provide a written medical clearance from their primary physician to participate in exercise - stable PD medications for 3 months Exclusion Criteria: - a Hoehn & Yahr staging greater than 2.5 at screening - severe cardiac disease (New York Heart Association classification IIIV) - history of an abnormal stress test - clinically significant medical or psychiatric illness - electrically, magnetically, or mechanically activated implant (such as cardiac pacemakers or intracerebral vascular clip) - metal in any part of the body including metal injury to the eye - past history of brain lesions (such as stroke) - seizures or unexplained spells of loss of consciousness - family history of epilepsy - physical therapy within 6 months of the study - symptomatic orthostatic hypotension at the screening visit - orthopedic and other movement-influencing diseases such as arthritis or total hip joint replacement - requirement for central nervous system active therapies (e.g. hypnotics, antidepressants, anxiolytics) - moderate or severe depression or apathy using the Geriatric depression scale and Apathy scale - taking anticholinesterase inhibitors - taking anticholinergic medication - PD dementia - Colorblindness |
Country | Name | City | State |
---|---|---|---|
United States | University of Southern California | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | National Parkinson Foundation, University of California, Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Context Dependent Motor Learning (CDML) | All subjects from each group will undergo a finger sequence motor learning task to determine exercise effects on EF as evaluated through improvement in the transfer of a learned motor task from one contextual setting to another. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Primary | Change in Dual Task Performance and Functional Magnetic Resonance Imaging (fMRI) | A subset of subjects (60 representing 20 per group) will be invited to undergo fMRI studies at University of California, Los Angeles. Patients will perform a learned single finger-sequencing task (a condition of the CDML) with an additional secondary dual task (DT) component during an fMRI scan. | at Baseline, after 12 week intervention | |
Primary | Change in D-KEFS Verbal Fluency Test | The D-KEFS Verbal Fluency test will be used to evaluate executive function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Primary | Change in Tower of London Test | The Tower of London test will be used to evaluate executive function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Primary | Change in Wisconsin Card Sorting Test | The Wisconsin Card Sorting test will be used to evaluate executive function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Parkinson Disease Questionnaire-39 (PDQ-39) | Parkinson Disease Questionnaire-39 (PDQ-39) will be used to indicate overall quality of life and frequency with which patients experience difficulties; high scores for the PDQ-39 reflect poorer quality of life. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Evaluation of PD Motor Symptoms with Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | The MDS-UPDRS is the established gold standard that is currently used for the vast majority of clinical settings and for scientific trials. This scale was developed in 1987 and is the most widely used tool in PD. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Activity Specific Balance Confidence (ABC) Scale | Activity Specific Balance Confidence (ABC) Scale is a 16-item self-report in which patients rate their balance confidence in performing several activities; high scores indicate greater balance confidence. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Confidence in ability to maintain an exercise program (CONF) | The CONF scale includes nine items, which assesses how sure subjects are that they would do exercise under different conditions or constraints, including when they are tired. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Exercise Control Beliefs (BEL) | The BEL, 6-item scale was developed to assess beliefs about control over exercise behavior. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Self-efficacy for Exercise Scale (EFFIC) | The EFFIC scale is a self-efficacy barriers to exercise measure, a 13-item instrument that focuses on self-efficacy expectations related to the ability to continue exercising in the face of barriers to exercise. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Frontal Systems Behavior Scale (FrSBe) | The FrSBe assesses changes in behavior dysfunction and disturbances associated with frontal-subcortical damage, which is the circuitry involved with executive functioning | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Motor Skill Fitness | An individual's Motor skill fitness will be a composite score of their Physical Performance Test (PPT) and their Timed Up and Go (TUG). | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Cardiovascular Fitness | Subjects will participate in testing designed to determine their level of cardiovascular fitness by estimating maximal oxygen uptake (V02max) known as the Balke treadmill submaximal fitness test and has been optimized for use in samples of elderly adults. | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Lifetime Total Physical Activity Questionnaire (LTPAQ) | The LPAQ measures the time spent in physical activity over the lifetime of the subject | at Baseline | |
Secondary | Change in Global Physical Activity Questionnaire (GPAQ) | The GPAQ measures the time spent in physical activity during a normal week | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Body Mass Index | at Baseline, after 12 week intervention, and at 12 week follow up visit | ||
Secondary | Change in Body Fat Percentage | at Baseline, after 12 week intervention, and at 12 week follow up visit | ||
Secondary | Change in Mattis Dementia Rating Scale | The Mattis Dementia Rating Scale will be used to differentiate between study subjects with mild cognitive impairment and dementia | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Geriatric Depression Scale | The Geriatric Depression Scale will be used to evaluate study subjects for depression | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Geriatric Anxiety Inventory | at Baseline, after 12 week intervention, and at 12 week follow up visit | ||
Secondary | Change in Apathy Scale | at Baseline, after 12 week intervention, and at 12 week follow up visit | ||
Secondary | Change in Revised Activities of Daily Living Scale | The Revised Activities of Daily Living Scale will be used to evaluate independent living skills | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in the Frontal Systems Behavior Scale (FrSBe) | The FrSBe will be used to evaluate frontal systems behavior | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Adaptive Digit Ordering Test | The Adaptive Digit Ordering Test will be used to evaluate attention and working memory | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Hooper Visual Organization Test | The Hooper Visual Organization Test will be used to evaluate visuospatial function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Benton's Judgment of Line Orientation | The Benton's Judgment of Line Orientation test will be used to evaluate visuospatial function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in D-KEFS Color Word Interference Test | The D-KEFS Color Word Interference Test will be used to evaluate attention, working memory and executive function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in California Verbal Learning Test- 2nd Edition (CVLT-II) | The CVLT-II will be used to evaluate memory function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in WMS-II Visual Reproduction Test | The WMS-II Visual Reproduction Test will be used to evaluate memory function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in WAIS-IV Similarities Test | The WAIS-IV Similarities test will be used to evaluate language function | at Baseline, after 12 week intervention, and at 12 week follow up visit | |
Secondary | Change in Boston Naming Test | The Boston Naming Test will be used to evaluate language function | at Baseline, after 12 week intervention, and at 12 week follow up visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02894567 -
Evaluation of Directional Recording and Stimulation Using spiderSTN
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |